The Technical Analyst
Lava Therapeutics B.V. [LVTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Lava Therapeutics B.V. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-8.05% $2.74
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 72.03 mill |
| EPS: | -1.570 |
| P/E: | -1.750 |
| Earnings Date: | Jun 06, 2024 |
| SharesOutstanding: | 26.29 mill |
| Avg Daily Volume: | 1.856 mill |
| RATING 2024-04-24 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.750 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.750 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-2.56 (-193.31%) $-5.30 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.28 - 3.20 ( +/- 16.72%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.75
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.75
Forecast 2: 16:00 - $2.75
Forecast 3: 16:00 - $2.75
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.74 (-8.05% ) |
| Volume | 0.154 mill |
| Avg. Vol. | 1.856 mill |
| % of Avg. Vol | 8.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LVTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:22 | sell | $1.660 | N/A | Active |
|---|
LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Latest Press Releases
2024-03-20 07:00:00 - Press Release
Lava Provides Business Updates And Reports Fourth Quarter And Year-end Financial Results
Utrecht, the netherlands and philadelphia, march 20, 2024 (globe newswire) -- lava therapeutics n.v. (nasdaq: lvtx, “lava,” “the company”), a clinical-stage immuno-oncology company focused on developing its proprietary gammabody® platform of bispecific gamma-delta (Δ2) t cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended december 31, 2023.
2024-03-05 07:30:00 - Press Release
Lava Announces Clinical Development Milestone Achieved By Pfizer for Pf-08046052 (formerly Sgn-egfrd2/lava-1223)
Milestone triggered by clinical progress in phase 1 study, initiated in q4 2023 milestone triggered by clinical progress in phase 1 study, initiated in q4 2023
2024-01-25 07:00:00 - Press Release
Lava Therapeutics Announces Collaboration With Merck & Co., Inc., Rahway, Nj, Usa To Evaluate Lava-1207 In Combination With Keytruda®
Collaboration will support the initiation of a combination arm in the ongoing phase 1/2a trial in patients with mcrpc enrollment will continue in the monotherapy and il-2 combination arms of the study utrecht, the netherlands and philadelphia, jan. 25, 2024 (globe newswire) -- lava therapeutics n.v. (nasdaq: lvtx), today announced that it has entered into a clinical trial collaboration and supply agreement with merck & co., inc., rahway, nj, usa to evaluate its anti-pd-1 therapy keytruda® (pembrolizumab) in combination with lava-1207, a gammabody® designed to target the prostate-specific membrane antigen (psma) to trigger the potent and preferential killing of psma-positive tumor cells, in patients with therapy refractory metastatic castration-resistant prostate cancer (mcrpc).
2023-11-16 07:00:00 - Press Release
Lava Therapeutics Provides Business Update And Reports Third Quarter 2023 Financial Results
Utrecht, the netherlands and philadelphia, nov. 16, 2023 (globe newswire) -- lava therapeutics n.v. (nasdaq: lvtx), a clinical-stage immuno-oncology company focused on developing its proprietary gammabody® platform of bispecific gamma-delta t cell engagers, today announced recent corporate highlights and financial results for the quarter ended september 30, 2023.
2023-09-06 07:11:00 - Press Release
Lava Therapeutics To Participate In The H.c. Wainwright 25th Annual Global Investment Conference
Utrecht, the netherlands and philadelphia, sept. 06, 2023 (globe newswire) -- lava therapeutics n.v. ( nasdaq: lvtx ), an immuno-oncology company focused on developing its proprietary gammabody™ platform of bispecific gamma-delta t cell engagers to transform the treatment of cancer, today announced that stephen hurly, president and chief executive officer of lava therapeutics, will participate in a virtual fireside chat at the h.c. wainwright 25th annual global investment conference which will be available on monday, september 11, 2023 at 7:00 am et.
Latest News
2023-09-06 07:11:00 - GlobeNewsWire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET.
2023-08-22 09:46:21 - Zacks Investment Research
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
LAVA Therapeutics N.V. (LVTX) came out with a quarterly loss of $0.48 per share in line with the Zacks Consensus Estimate.
2023-06-15 10:47:08 - Zacks Investment Research
Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall
Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.
2023-06-02 12:09:07 - Zacks Investment Research
LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.
2023-02-09 07:00:00 - GlobeNewsWire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference.
2023-01-23 07:00:00 - GlobeNewsWire
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.
2023-01-03 07:00:00 - GlobeNewsWire
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.
2022-11-25 11:17:17 - Zacks Investment Research
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock.
2022-11-16 18:48:10 - Zacks Investment Research
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022.
2022-10-18 02:32:12 - Seeking Alpha
LAVA Therapeutics: Assessing A Promising Innovator
LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors. The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy.